NYSE: BAX
Baxter International Inc Stock

$30.81-0.66 (-2.1%)
Updated Feb 6, 2025
BAX Price
$30.81
Fair Value Price
N/A
Market Cap
$15.73B
52 Week Low
$28.34
52 Week High
$44.01
P/E
146.71x
P/B
2x
P/S
1.38x
PEG
0.62x
Dividend Yield
2.43%
Revenue
$13.99B
Earnings
$108.00M
Gross Margin
38.1%
Operating Margin
5.25%
Profit Margin
0.8%
Debt to Equity
2.38
Operating Cash Flow
$1B
Beta
0.64
Next Earnings
Feb 13, 2025
Ex-Dividend
N/A
Next Dividend
N/A

BAX Overview

Baxter International Inc. manufacturfes products to treat kidney disease and other chronic and acute medical conditions. Baxter's BioScience business produces recombinant and blood plasma proteins to treat hemophilia and other bleeding disorders, as well as plasma-based therapies to treat immune deficiencies and other chronic and acute blood-related conditions. Baxter's Medical Products segment produces intravenous and other products to deliver fluids and drugs to patients, inhalational anaesthetics, and contract manufacturing services. The company was founded in 1931 and is headquartered in Deerfield, IL.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine BAX's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

B
Value
C
Growth
D
Momentum
C
Sentiment
B
Safety
C
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Medical

Industry Rating
A
BAX
Ranked
#34 of 49

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$8.05A
$34.34A
$17.73A
View Top Medical Stocks

Be the first to know about important BAX news, forecast changes, insider trades & much more!

BAX News

Overview

Due Diligence Score

Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BAX scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BAX ($30.81) is trading above its intrinsic value of $18.30, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BAX is poor value based on its earnings relative to its share price (146.71x), compared to the US market average (31.69x)
P/E vs Market Valuation
BAX is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more BAX due diligence checks available for Premium users.

Valuation

BAX price to earnings (PE)

For valuing profitable companies with steady earnings

Company
146.71x
Industry
37.55x
Market
31.69x
BAX is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
BAX is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation

BAX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
2x
Industry
4.12x
BAX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

BAX price to earnings growth (PEG)

For valuing profitable companies with growth potential

BAX is good value based... subscribe to Premium to read more.
PEG Value Valuation

BAX's financial health

Profit margin

Revenue
$2.7B
Net Income
$140.0M
Profit Margin
5.2%
BAX's Earnings (EBIT) of $735.00M... subscribe to Premium to read more.
Interest Coverage Financials
BAX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$26.7B
Liabilities
$18.7B
Debt to equity
2.38
BAX's short-term assets ($8.86B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BAX's long-term liabilities ($12.53B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BAX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
BAX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$253.0M
Investing
-$164.0M
Financing
-$146.0M
BAX's operating cash flow ($1.06B)... subscribe to Premium to read more.
Debt Coverage Financials

BAX vs Medical Stocks

TickerZen RatingMarket Cap1d %P/EP/B
BAXC$15.73B-2.10%146.71x2.00x
HOLXC$14.69B-10.10%20.52x3.08x
COOC$19.02B-1.43%48.37x2.35x
ATRC$10.41B-1.18%30.80x4.10x
RGENB$9.07B-0.04%-1,156.14x4.50x

Baxter International Stock FAQ

What is Baxter International's quote symbol?

(NYSE: BAX) Baxter International trades on the NYSE under the ticker symbol BAX. Baxter International stock quotes can also be displayed as NYSE: BAX.

If you're new to stock investing, here's how to buy Baxter International stock.

What is the 52 week high and low for Baxter International (NYSE: BAX)?

(NYSE: BAX) Baxter International's 52-week high was $44.01, and its 52-week low was $28.34. It is currently -29.99% from its 52-week high and 8.73% from its 52-week low.

How much is Baxter International stock worth today?

(NYSE: BAX) Baxter International currently has 510,587,581 outstanding shares. With Baxter International stock trading at $30.81 per share, the total value of Baxter International stock (market capitalization) is $15.73B.

Baxter International stock was originally listed at a price of $25.22 in Dec 31, 1997. If you had invested in Baxter International stock at $25.22, your return over the last 27 years would have been 22.16%, for an annualized return of 0.74% (not including any dividends or dividend reinvestments).

How much is Baxter International's stock price per share?

(NYSE: BAX) Baxter International stock price per share is $30.81 today (as of Feb 6, 2025).

What is Baxter International's Market Cap?

(NYSE: BAX) Baxter International's market cap is $15.73B, as of Feb 7, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Baxter International's market cap is calculated by multiplying BAX's current stock price of $30.81 by BAX's total outstanding shares of 510,587,581.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.